CA2762009C - Use of pufas to treat nerve damage - Google Patents

Use of pufas to treat nerve damage Download PDF

Info

Publication number
CA2762009C
CA2762009C CA2762009A CA2762009A CA2762009C CA 2762009 C CA2762009 C CA 2762009C CA 2762009 A CA2762009 A CA 2762009A CA 2762009 A CA2762009 A CA 2762009A CA 2762009 C CA2762009 C CA 2762009C
Authority
CA
Canada
Prior art keywords
group
alkyl
cis
unsubstituted
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2762009A
Other languages
English (en)
French (fr)
Other versions
CA2762009A1 (en
Inventor
Adam Kelliher
Norman Cameron
Angus Morrison
Phil Knowles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Pharma Callanish Ltd
Original Assignee
Equateq Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equateq Ltd filed Critical Equateq Ltd
Publication of CA2762009A1 publication Critical patent/CA2762009A1/en
Application granted granted Critical
Publication of CA2762009C publication Critical patent/CA2762009C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2762009A 2009-05-01 2010-04-22 Use of pufas to treat nerve damage Expired - Fee Related CA2762009C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods
GB0907601.9 2009-05-01
PCT/GB2010/000817 WO2010125330A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Publications (2)

Publication Number Publication Date
CA2762009A1 CA2762009A1 (en) 2010-11-04
CA2762009C true CA2762009C (en) 2016-11-22

Family

ID=40792178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2762009A Expired - Fee Related CA2762009C (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Country Status (14)

Country Link
US (1) US20120122982A1 (cg-RX-API-DMAC10.html)
EP (1) EP2424519A1 (cg-RX-API-DMAC10.html)
JP (1) JP5608220B2 (cg-RX-API-DMAC10.html)
KR (1) KR101664518B1 (cg-RX-API-DMAC10.html)
CN (1) CN102448453B (cg-RX-API-DMAC10.html)
AU (1) AU2010243368C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1009922A2 (cg-RX-API-DMAC10.html)
CA (1) CA2762009C (cg-RX-API-DMAC10.html)
GB (1) GB0907601D0 (cg-RX-API-DMAC10.html)
MX (1) MX2011011615A (cg-RX-API-DMAC10.html)
NZ (1) NZ596674A (cg-RX-API-DMAC10.html)
SG (1) SG175848A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010125330A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201108571B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
ES2727387T3 (es) * 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3261684D1 (en) * 1981-05-12 1985-02-07 Ici Plc Pyrrole derivatives
US4532254A (en) * 1983-03-17 1985-07-30 Kaken Pharmaceutical Co., Ltd. Inhibitor of aldose reductase
AU599515B2 (en) * 1987-09-16 1990-07-19 Taiho Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
EP2140863A1 (en) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
ES2240657T3 (es) * 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
ES2536710T3 (es) * 2002-03-25 2015-05-27 Arimed Inc. Nuevo uso terapéutico de LPC, ligandos agonistas específicos para el receptor G2A
WO2006137435A1 (ja) * 2005-06-22 2006-12-28 National University Corporation Gunma University Gタンパク質共役型受容体g2aの作動薬、及びg2a活性調節薬のスクリーニング方法
EP2179999A4 (en) * 2007-12-18 2011-06-08 Univ Toyama Nat Univ Corp CONDENSED TRICYCLIC COMPOUND WITH ALDOSIS REDUCTASE HARMFUL EFFECT

Also Published As

Publication number Publication date
JP5608220B2 (ja) 2014-10-15
AU2010243368A1 (en) 2011-12-15
EP2424519A1 (en) 2012-03-07
AU2010243368C1 (en) 2014-04-03
GB0907601D0 (en) 2009-06-10
KR20120023729A (ko) 2012-03-13
SG175848A1 (en) 2011-12-29
AU2010243368B2 (en) 2013-10-24
CA2762009A1 (en) 2010-11-04
KR101664518B1 (ko) 2016-10-11
WO2010125330A1 (en) 2010-11-04
NZ596674A (en) 2013-09-27
JP2012525362A (ja) 2012-10-22
BRPI1009922A2 (pt) 2016-03-15
MX2011011615A (es) 2012-01-27
US20120122982A1 (en) 2012-05-17
CN102448453A (zh) 2012-05-09
CN102448453B (zh) 2016-07-06
ZA201108571B (en) 2013-01-30

Similar Documents

Publication Publication Date Title
Lee et al. Palmitic acid methyl ester is a novel neuroprotective agent against cardiac arrest
EA035649B1 (ru) Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства
CA2824317A1 (en) Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
KR20170125951A (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
AU2010243368C1 (en) Use of PUFAs to treat nerve damage
CN117377476B (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛
US20200197326A1 (en) Topical pharmaceutical composition comprising at least amitriptyline, for the treatment of peripheral neuropathic pain
JP2016540771A (ja) セロトニン−ノルアドレナリン再取り込み阻害薬(snri)およびシグマ受容体リガンドの組み合わせ
JP5077893B2 (ja) 環状ホスファチジン酸誘導体を含む鎮痛剤
JP2006143708A (ja) 神経変性疾患治療用医薬
CN115745890B (zh) 一种酯键化合物及其制备方法和应用、镇痛药物
AU2006275824B2 (en) Method of improving wakefulness
JP2012525362A5 (cg-RX-API-DMAC10.html)
US20200368310A1 (en) Treatment with nmda receptor modulators
KR102721799B1 (ko) 신규한 카나비디올 유도체, 이의 제조 방법 및 이를 포함하는 파킨슨병의 예방 또는 치료용 조성물
Yuan et al. Progress on Omega-3 fatty acids for the comprehensive and targeted treatment of spinal cord injury
US8975298B2 (en) Therapeutic agent for pain
CN116987091B (zh) 用于治疗癫痫发作疾病的药物及其制备方法
JP2020033272A (ja) 過活動膀胱の予防又は改善剤
ES2808667T3 (es) Derivados de diarilmetilideno piperidina y su uso como agonistas del receptor opioide delta
Jang et al. Effects of propofol administration rates on cardiopulmonary function and anaesthetic depth during anaesthetic induction in rats
KR20250071888A (ko) 신규한 카나비디올 유도체, 이의 제조방법 및 이를 포함하는 뇌전증 치료용 약학 조성물
KR20250010571A (ko) 신규한 고리 구조의 트리아졸 화합물, 이의 제조방법 및 이의 용도
JP6216913B1 (ja) 医薬組成物
WO2020262317A1 (ja) 認知症の治療及び予防薬

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140204

MKLA Lapsed

Effective date: 20180423